Cargando…

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

BACKGROUND: Although it is accepted that metastatic colorectal cancers (mCRCs) that carry activating mutations in KRAS are unresponsive to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, a significant fraction of KRAS wild-type (wt) mCRCs are also unresponsive to anti-EGFR therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, J B, Dutta, D, Watson, D, Maddala, T, Munneke, B M, Shak, S, Rowinsky, E K, Xu, L-A, Harbison, C T, Clark, E A, Mauro, D J, Khambata-Ford, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049558/ https://www.ncbi.nlm.nih.gov/pubmed/21206494 http://dx.doi.org/10.1038/sj.bjc.6606054

Ejemplares similares

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
por: Knijn, N, et al.
Publicado: (2011)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
por: Frattini, M, et al.
Publicado: (2007)

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
por: Gonzalez de Castro, D, et al.
Publicado: (2012)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma
por: Dutta, S, et al.
Publicado: (2012)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
por: West, N R, et al.
Publicado: (2013)

Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study
por: Horsch, M, et al.
Publicado: (2009)

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
por: Deschoolmeester, V, et al.
Publicado: (2010)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
por: van Grieken, N C T, et al.
Publicado: (2013)

PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness
por: Molleví, D G, et al.
Publicado: (2008)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment
por: Slade, M J, et al.
Publicado: (2009)

Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive
por: O'Toole, A, et al.
Publicado: (2014)

Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma
por: Baldan, V, et al.
Publicado: (2015)

Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells
por: Boudreau, H E, et al.
Publicado: (2014)

Objective assessment of tumour response to therapy based on tumour growth kinetics
por: Mehrara, E, et al.
Publicado: (2011)

Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer
por: Morrison, D H, et al.
Publicado: (2012)

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer
por: Rao, S R, et al.
Publicado: (2017)

Tumour morphology predicts PALB2 germline mutation status
por: Teo, Z L, et al.
Publicado: (2013)

Isolation of tumour stem-like cells from benign tumours
por: Xu, Q, et al.
Publicado: (2009)

Testicular microlithiasis as a familial risk factor for testicular germ cell tumour
por: Coffey, J, et al.
Publicado: (2007)

Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours
por: Skliris, G P, et al.
Publicado: (2006)

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition
por: Hamidi, H, et al.
Publicado: (2014)

Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer
por: Öhlund, D, et al.
Publicado: (2009)

Death-associated protein 3 is overexpressed in human thyroid oncocytic tumours
por: Jacques, C, et al.
Publicado: (2009)

The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer
por: Gujam, F J A, et al.
Publicado: (2015)

Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness
por: Weiswald, L-B, et al.
Publicado: (2009)

Clinical significance of disseminated tumour cells in non-small cell lung cancer
por: Rud, A K, et al.
Publicado: (2013)

ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival
por: Brüning-Richardson, A, et al.
Publicado: (2011)

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes
por: Pinato, D J, et al.
Publicado: (2014)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas
por: Deb, S, et al.
Publicado: (2014)

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?
por: Saridaki, Z, et al.
Publicado: (2015)

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer
por: Ankeny, J S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_iidejldhe652i2mfgmthh09544